Camber Launches Generic Neurontin® Oral Solution

Piscataway, NJ, July 19, 2024 – Camber Pharmaceuticals is pleased to announce the addition of Gabapentin Oral Solution to its product line. Camber also offers Gabapentin Tablets and Capsules.
Gabapentin Oral Solution is indicated for:
-
-
- Management of Postherpetic Neuralgia in adults
- Adjunctive therapy in the treatment of partial onset seizures, with and without secondary generalization, in adults and pediatric patients 3 years and older with epilepsy
-
Gabapentin Oral Solution is available in a 470 mL bottle with a concentration of 250 mg per 5 mL.
To learn more about Gabapentin Oral Solution, please visit https://www.camberpharma.com/gabapentinoralsolution
Recent articles
- Camber Launches Temozolomide Capsules, USP
- Camber Launches Eltrombopag Tablets & Oral Suspension
- Camber Launches Eslicarbazepine Acetate Tablets
- Camber Launches Phenylephrine Hydrochloride Injection, USP
- Camber Launches Chlorzoxazone Tablets, USP
- Camber Launches 13 New Generic Products in Q1 2025, Sets Ambitious Pace for the Year